Several other research firms have also issued reports on TNDM. Oppenheimer lowered their price target on shares of Tandem Diabetes Care from $142.00 to $130.00 in a report on Thursday, May 5th. Bank of America assumed coverage on shares of Tandem Diabetes Care in a research note on Wednesday, March 2nd. They set a neutral rating and a $130.00 target price for the company. Piper Sandler cut their price target on shares of Tandem Diabetes Care from $170.00 to $120.00 in a research report on Thursday, May 5th. Wells Fargo & Company increased their price target on Tandem Diabetes Care from $160.00 to $166.00 and gave the stock an overweight rating in a report on Wednesday, February 23rd. Finally, Citigroup dropped their price objective on Tandem Diabetes Care from $163.00 to $155.00 and set a buy rating on the stock in a research note on Wednesday, February 23rd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care has a consensus rating of Hold and a consensus target price of $137.55.
NASDAQ TNDM opened at $67.78 on Tuesday. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 847.36 and a beta of 0.66. The company has a quick ratio of 5.63, a current ratio of 6.21 and a debt-to-equity ratio of 0.64. Tandem Diabetes Care has a twelve month low of $67.03 and a twelve month high of $155.86. The stock has a fifty day simple moving average of $107.72 and a 200 day simple moving average of $121.93.
In other Tandem Diabetes Care news, CFO Leigh Vosseller purchased 500 shares of the firm’s stock in a transaction on Monday, May 9th. The stock was acquired at an average price of $70.00 per share, for a total transaction of $35,000.00. Following the purchase, the chief financial officer now owns 9,118 shares of the company’s stock, valued at approximately $638,260. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathleen Mcgroddy-Goetz sold 405 shares of the company’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of $106.00, for a total transaction of $42,930.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 5,000 shares of company stock worth $361,270 and have sold 8,153 shares worth $870,264. 4.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in TNDM. Moors & Cabot Inc. bought a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $25,000. Exane Derivatives purchased a new position in shares of Tandem Diabetes Care during the first quarter valued at approximately $33,000. Byrne Asset Management LLC bought a new stake in Tandem Diabetes Care during the fourth quarter worth $34,000. Sandy Cove Advisors LLC purchased a new stake in Tandem Diabetes Care in the 1st quarter valued at $46,000. Finally, Retirement Planning Co of New England Inc. purchased a new stake in Tandem Diabetes Care in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 94.62% of the company’s stock.
Tandem Diabetes Care Company Profile (Get Rating)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.